Wilson's Disease

1. Clinical Overview

Summary

Wilson's Disease is a rare autosomal recessive disorder of copper metabolism caused by mutations in the ATP7B gene on chromosome 13q14.3. This genetic defect leads to impaired biliary excretion of copper and defective incorporation of copper into ceruloplasmin, resulting in toxic accumulation of copper in the liver, brain, cornea, and other organs. [1,2]

Clinical manifestations are highly variable, ranging from asymptomatic hepatic transaminitis discovered incidentally to fulminant hepatic failure, cirrhosis with portal hypertension, and progressive neuropsychiatric disease (parkinsonism, dystonia, tremor, psychiatric symptoms). The pathognomonic Kayser-Fleischer rings (golden-brown copper deposits in Descemet's membrane of the cornea) are present in approximately 95% of patients with neurological involvement but only 50-60% of those with purely hepatic disease. [2,3]

Diagnosis relies on a combination of clinical features, low serum ceruloplasmin (less than 0.2 g/L in ~95% of cases), elevated 24-hour urinary copper (> 100 μg/24h), increased hepatic copper content on liver biopsy (> 250 μg/g dry weight), and ATP7B genetic testing. The Leipzig scoring system provides a structured diagnostic approach, with scores ≥4 indicating high probability of Wilson's disease. [3,4]

Treatment requires lifelong therapy with copper chelation agents (D-penicillamine, trientine) and/or zinc salts (which block intestinal copper absorption). Liver transplantation is curative for fulminant hepatic failure or decompensated cirrhosis, providing a liver with functional ATP7B expression. Without treatment, Wilson's disease is universally fatal; with early diagnosis and appropriate treatment, prognosis is excellent with normal life expectancy. Family screening of first-degree relatives is mandatory given the autosomal recessive inheritance pattern. [1,5]

Clinical Pearls

"Think Wilson's in Any Young Person with Unexplained Liver or Neurological Disease": Wilson's disease should be considered in ALL patients under 40 years with unexplained liver disease of any severity, and in ANY young person presenting with movement disorders, psychiatric symptoms, or cognitive decline. The median age of diagnosis is 13 years for hepatic presentations and 21 years for neurological presentations. [2]

Kayser-Fleischer Rings are Pathognomonic but Not Always Present: These brownish-green or golden rings at the corneal limbus are virtually diagnostic when present, but their absence does not exclude Wilson's disease. They are best visualized by slit-lamp examination by an experienced ophthalmologist—naked eye examination misses up to 50% of cases. KF rings result from copper deposition in Descemet's membrane and are present in ~95% of neurological Wilson's but only ~50% of purely hepatic presentations. [3,6]

Acute Liver Failure + Coombs-Negative Haemolysis = Wilson's Until Proven Otherwise: This combination is highly characteristic. The sudden release of hepatic copper causes direct oxidative damage to red blood cells, producing Coombs-negative haemolytic anaemia. Additional features include: disproportionately low alkaline phosphatase (ALP:total bilirubin ratio less than 4), elevated serum copper (paradoxically), and rapid deterioration. Wilson's disease accounts for 10-15% of acute liver failure in adolescents and young adults. [7,8]

The "Neurological Paradox" of Penicillamine: Up to 50% of patients with neurological Wilson's disease experience transient worsening of neurological symptoms (paradoxical deterioration) during the first 2-6 months of penicillamine therapy. This may result from mobilization of hepatic copper stores with redistribution to the brain. Consider starting with trientine or zinc in neurological presentations, or using very low-dose penicillamine escalation. [5,9]

Family Screening is Essential and Cost-Effective: With autosomal recessive inheritance, siblings have a 25% chance of being affected and a 50% chance of being carriers. Presymptomatic diagnosis and treatment of affected siblings prevents irreversible organ damage. Screen all first-degree relatives with ceruloplasmin, liver function tests, slit-lamp examination, and 24-hour urinary copper. If the proband's mutations are identified, targeted genetic testing is highly efficient. [10,11]

Normal Ceruloplasmin Does Not Exclude Wilson's Disease: Approximately 5% of patients with confirmed Wilson's disease have ceruloplasmin levels in the low-normal range. Ceruloplasmin is also an acute-phase reactant and may be elevated during inflammation, pregnancy, or estrogen therapy. Never rely on ceruloplasmin alone—always combine with urinary copper excretion and clinical features. [3,12]

Hepatic vs Neurological Presentations Show Distinct Age Patterns: Hepatic presentations typically occur earlier (median age 13 years, range 5-35) while neurological presentations peak later (median age 21 years, range 10-50+). Pure hepatic presentations are more common in children and adolescents, whereas adult-onset Wilson's disease more frequently presents with neurological or psychiatric features. This age-phenotype correlation relates to the biphasic pathophysiology: initial hepatic copper accumulation followed by systemic release. [2,18]

---

2. Epidemiology

Incidence and Prevalence

• Prevalence: Approximately 1 in 30,000 to 1 in 50,000 in most populations, with regional variations. Prevalence is higher in populations with consanguinity. [1,2]
• Carrier frequency: Approximately 1 in 90 to 1 in 100 individuals carry one mutant ATP7B allele and are asymptomatic heterozygotes. [13]
• Geographic variation: Higher prevalence reported in Sardinia (1 in 7,000), Crete, and some isolated populations due to founder effects. [2]

Age and Sex Distribution

• Age of onset: Most patients present between 5 and 35 years, though presentation outside this range occurs:
  • "Hepatic presentations: Peak age 8-16 years"
  • "Neurological presentations: Peak age 19-25 years"
  • Rare presentations in infancy (less than 3 years) and adults > 40 years
• Sex distribution: Equal prevalence in males and females (autosomal recessive), though some studies suggest males may present with more severe hepatic disease. [1,14]

Genetics

ATP7B Gene

• Location: Chromosome 13q14.3
• Gene product: ATP7B protein, a P-type copper-transporting ATPase expressed primarily in hepatocytes
• Protein function:
  • Transports copper from cytoplasm into trans-Golgi network for incorporation into ceruloplasmin
  • Exports excess copper into bile canaliculi for excretion
  • Contains 6 copper-binding domains and 1,465 amino acids [15]

Mutation Spectrum

• Over 900 different mutations have been identified in ATP7B, including missense, nonsense, splice-site, and deletion mutations. [2,13]
• H1069Q mutation (histidine to glutamine at position 1069):
  • Most common mutation in European populations (40-80% of disease alleles in Central/Eastern Europe)
  • Located in the ATP-binding domain
  • Associated with later onset and predominantly neurological presentation
  • Typically seen in compound heterozygotes [16]
• Other common mutations by population:
  • "R778L: Common in Asian populations (especially China, Japan)"
  • "P1148L: Seen in northern European populations"
  • "E1064A: Middle Eastern populations"
  • "M769HfsX26: Common in Sardinian population [13,15]"

Genotype-Phenotype Correlations

• Truncating mutations (nonsense, frameshift) generally associate with earlier onset and more severe hepatic disease
• H1069Q homozygotes tend to present later (greater than 20 years) with neurological symptoms
• Compound heterozygotes (two different mutations) show variable phenotypes
• Loss-of-function (LOF) variants: Recent studies demonstrate worse survival with chronic liver disease in patients carrying two LOF mutations, with increased risk of decompensation and need for transplantation [16,35]
• Missense mutations in copper-binding domains: May retain partial function, associated with milder phenotype and later onset
• Important caveat: Significant clinical variability exists even among siblings with identical mutations, suggesting modifier genes and environmental factors influence phenotype. [13,16]

---

3. Pathophysiology

Molecular Basis

Normal Copper Homeostasis

1. Dietary copper intake: Average 1-3 mg/day, primarily absorbed in duodenum and proximal jejunum via CTR1 (copper transporter 1)
2. Hepatic uptake: Copper enters hepatocytes bound to albumin and is delivered to copper chaperones
3. Intracellular trafficking:
   • ATOX1 chaperone delivers copper to ATP7B in trans-Golgi network
   • CCS (copper chaperone for SOD1) delivers copper to cytoplasmic Cu/Zn superoxide dismutase
   • COX17 delivers copper to mitochondrial cytochrome c oxidase
4. Biliary excretion: ATP7B translocates to canalicular membrane under high copper conditions and actively exports copper into bile (primary excretory route, ~1-2 mg/day)
5. Ceruloplasmin synthesis: ATP7B incorporates 6 copper atoms into apoceruloplasmin in Golgi, producing functional holoceruloplasmin (95% of serum copper is ceruloplasmin-bound) [1,15,17]

Pathological Copper Accumulation in Wilson's Disease

Phase 1: Hepatic Accumulation (Childhood to Adolescence)

1. Defective ATP7B function: Mutant ATP7B protein has impaired copper transport capacity
2. Impaired ceruloplasmin synthesis: Without copper incorporation, apoceruloplasmin is rapidly degraded (half-life less than 5 hours vs 5.5 days for holoceruloplasmin), resulting in low serum ceruloplasmin
3. Impaired biliary excretion: Copper accumulates in hepatocytes, initially in cytosol bound to metallothionein
4. Hepatic copper concentration increases: From normal less than 50 μg/g dry weight to > 250 μg/g (often > 1000 μg/g)
5. Oxidative stress: Free copper catalyzes Fenton reactions, generating reactive oxygen species (ROS) that damage lipids, proteins, and DNA
6. Hepatocyte injury: Manifests as steatosis, hepatitis, fibrosis, and eventually cirrhosis [1,15,17]

Phase 2: Systemic Copper Release (Adolescence to Adulthood)

1. Hepatocyte necrosis: As hepatocytes die from copper toxicity, stored copper is released into circulation
2. Non-ceruloplasmin-bound copper increases: Free (labile) copper in serum rises, causing systemic toxicity
3. Extrahepatic deposition:
   • Brain (basal ganglia): Preferential deposition in putamen, globus pallidus, caudate nucleus, and thalamus
   • Cornea (Descemet's membrane): Kayser-Fleischer rings
   • Kidneys: Proximal tubular damage (Fanconi syndrome)
   • Heart, bones, joints, parathyroid: Less common sites [2,18]

Organ-Specific Pathophysiology

Hepatic Manifestations

• Steatosis: Early manifestation; copper disrupts mitochondrial β-oxidation and lipid metabolism
• Chronic hepatitis: Necroinflammation with lymphocytic infiltration, ballooning degeneration
• Fibrosis and cirrhosis: Progressive fibrosis leads to micronodular cirrhosis; portal hypertension develops
• Acute liver failure: Massive hepatocyte necrosis with sudden copper release; associated with:
  • Coombs-negative haemolytic anaemia (copper damages RBC membranes)
  • "Low ALP (hepatocyte necrosis reduces synthesis): ALP:total bilirubin ratio less than 4 is 94% specific for Wilson's in ALF"
  • Very high serum copper (> 2.5 μmol/L)
  • Coagulopathy and hepatic encephalopathy [7,8,18]

Neurological Manifestations (Hepatolenticular Degeneration)

• Pathological findings:
  • Neuronal loss and gliosis in basal ganglia (putamen, globus pallidus, caudate)
  • Astrocyte swelling and proliferation (Alzheimer type II astrocytes)
  • Cavitation and cyst formation in severe cases
  • Thalamic, brainstem, cerebellar involvement in advanced disease
• MRI findings:
  • T2/FLAIR hyperintensity in basal ganglia, thalamus, midbrain
  • "Face of the Giant Panda" sign: hyperintense tegmentum with preserved hypointense red nuclei and superior colliculi
  • "Eye of the Tiger" appearance in some cases (bilateral putaminal hyperintensity with central hypointensity)
  • Brain atrophy in chronic untreated cases [18,19]
• Clinical-pathological correlation:
  • "Putamen: Dystonia, rigidity"
  • "Globus pallidus: Bradykinesia, parkinsonism"
  • "Caudate: Chorea, personality changes"
  • "Thalamus: Tremor, sensory abnormalities"
  • "Cortical involvement: Cognitive decline, psychiatric symptoms [5,19]"

Renal Manifestations

• Proximal tubular dysfunction: Copper deposits in proximal tubules cause Fanconi syndrome
  • Aminoaciduria
  • Glucosuria (with normal blood glucose)
  • Phosphaturia (hypophosphatemia)
  • Proximal renal tubular acidosis (type 2 RTA)
  • Uricosuria (hypouricemia)
• Nephrolithiasis: Increased calcium and uric acid excretion
• Glomerular abnormalities: Rare; may cause proteinuria or haematuria [20]

Haematological Manifestations

• Coombs-negative haemolytic anaemia: Occurs during acute copper release
  • Direct copper-induced oxidative damage to RBC membranes
  • Spherocytes, fragmented RBCs on blood film
  • Elevated unconjugated bilirubin, elevated LDH, low haptoglobin
  • Negative direct antiglobulin test (DAT)
• Thrombocytopenia: May occur in cirrhosis with hypersplenism [7,8]

Skeletal Manifestations

• Osteoporosis: Premature bone loss, often before diagnosis
• Osteomalacia: Due to renal phosphate wasting
• Arthropathy: Particularly affecting knees, wrists, spine
  • Chondrocalcinosis (pseudo-gout)
  • Joint effusions, premature osteoarthritis [2,20]

Cardiac Manifestations

• Cardiomyopathy: Rare; dilated or restrictive patterns
• Arrhythmias: Atrial and ventricular arrhythmias reported
• Autonomic dysfunction: Orthostatic hypotension, syncope [20]

Endocrine Manifestations

• Hypoparathyroidism: Copper deposition in parathyroid glands; hypocalcemia
• Delayed puberty: In children with severe untreated disease
• Amenorrhea: In females with advanced disease
• Infertility: Reversible with treatment [20]

---

4. Differential Diagnosis

Hepatic Presentations

Neurological Presentations

Acute Liver Failure

---

5. Clinical Presentation

Hepatic Manifestations (~40-50%)

Wilson's disease can present with the full spectrum of liver disease:

Asymptomatic Hepatic Involvement

• Incidentally discovered transaminitis: Mild to moderate elevation of ALT/AST (2-5× upper limit normal)
• Hepatomegaly: May be only physical finding
• Detected through family screening: Presymptomatic siblings of index cases [2,21]

Acute Hepatitis

• Clinical features: Fatigue, anorexia, nausea, jaundice, abdominal pain
• Laboratory: ALT/AST 500-2000 IU/L, bilirubin elevation
• May mimic: Acute viral hepatitis, drug-induced liver injury
• Key clue: Young age, absence of viral serology, persistence beyond expected timeframe [21]

Chronic Hepatitis

• Indolent course: Progressive fatigue, intermittent jaundice
• Physical findings: Hepatomegaly, mild splenomegaly
• Histology: Chronic inflammation, steatosis, varying degrees of fibrosis
• May be misdiagnosed: As autoimmune hepatitis, NAFLD [21]

Cirrhosis and Portal Hypertension

• Compensated cirrhosis: May be asymptomatic initially
• Decompensated cirrhosis:
  • Ascites (most common decompensation event)
  • Variceal hemorrhage (esophageal or gastric varices)
  • Hepatic encephalopathy
  • Spontaneous bacterial peritonitis
• Physical findings: Spider nevi, palmar erythema, caput medusae, splenomegaly
• Important: Some patients present with cirrhosis as first manifestation, with no prior diagnosis of liver disease [18,21]

Fulminant Hepatic Failure (Acute Liver Failure)

• Rapid onset: Coagulopathy and encephalopathy developing within 26 weeks of first symptom
• Age: Typically adolescents and young adults (10-30 years)
• Hallmark features:
  • "Coombs-negative haemolytic anaemia (direct copper toxicity to RBCs): Present in 50-100% of cases"
  • Very high bilirubin (often > 20 mg/dL, can exceed 50 mg/dL)
  • "Disproportionately low alkaline phosphatase: ALP:total bilirubin ratio less than 4 (94% specific, 84% sensitive)"
  • "AST:ALT ratio > 2.2 (often > 4)"
  • Very high serum copper (> 2.5 μmol/L due to release from necrotic hepatocytes)
  • "Acute kidney injury: Often due to hepatorenal syndrome or haemolysis-related acute tubular necrosis"
  • "Thrombocytopenia: Multifactorial (hypersplenism, bone marrow suppression)"
• Prognosis: Grave without liver transplantation; medical therapy alone rarely successful
• Wilson's scoring for ALF: Various scoring systems exist to predict need for transplant (New Wilson Index, revised King's College criteria) [7,8,22]

Neurological Manifestations (~40%)

Neurological Wilson's disease typically presents in the second or third decade (range 10-50+ years). Neurological symptoms almost always occur with established cirrhosis (often compensated and undiagnosed). [5,19]

Movement Disorders

Dystonia (Most common, 60-70%)

• Characteristics: Sustained muscle contractions, twisting movements, abnormal postures
• Distribution:
  • "Focal: Torticollis, blepharospasm, writer's cramp"
  • "Segmental: Affecting contiguous body regions"
  • "Generalized: Affecting trunk and at least two other sites"
• Facial dystonia: Risus sardonicus (fixed smile), jaw opening/closure dystonia
• Laryngeal dystonia: Contributes to dysarthria and dysphagia
• Can be painful: Especially cervical dystonia [5,19]

Tremor (50-60%)

• Types:
  • "Postural/action tremor: Most common"
  • ""Wing-beating" tremor: Proximal, high-amplitude tremor of shoulders and arms when arms extended"
  • "Resting tremor: Less common than in Parkinson's disease"
  • "Intention tremor: Cerebellar involvement"
• Severe cases: Can be functionally disabling, interfering with eating, writing [5]

Parkinsonism (20-50%)

• Features: Bradykinesia, rigidity, masked facies, shuffling gait
• Differences from idiopathic Parkinson's:
  • Younger age
  • Symmetric rather than asymmetric
  • Poor or no response to levodopa
  • More prominent dystonia and tremor
  • Kayser-Fleischer rings present [5,19]

Chorea (10-15%)

• Irregular, brief, rapid, involuntary movements
• Can mimic Huntington's disease
• Often combined with dystonia ("choreo-dystonic" pattern) [5]

Ataxia (20-30%)

• Cerebellar ataxia: Gait instability, limb incoordination, intention tremor
• Sensory ataxia: Rare; due to dorsal column involvement
• MRI may show cerebellar atrophy in advanced cases [19]

Bulbar Dysfunction

Dysarthria (90% of neurological cases)

• Characteristics: Slurred, hypophonic, monotonous speech
• Types: Mixed spastic-rigid-ataxic dysarthria
• Severity: Can progress to complete anarthria
• Important diagnostic clue: Often the presenting symptom; may be misattributed to alcohol or drugs [5,23]

Dysphagia

• Oropharyngeal dysphagia: Difficulty initiating swallows
• Esophageal dysphagia: Less common
• Complications: Aspiration pneumonia, weight loss, malnutrition
• Assessment: Video-fluoroscopic swallow study if clinically significant [5]

Sialorrhea (Drooling)

• Due to impaired swallowing rather than excess saliva production
• Socially embarrassing; can lead to skin irritation
• May improve with anticholinergic therapy or botulinum toxin injections [5]

Cognitive and Behavioral Manifestations

Executive Dysfunction (Most common cognitive deficit)

• Impaired planning, organization, abstract thinking
• Poor judgment and decision-making
• Reduced mental flexibility
• Frontostriatal pattern: Consistent with basal ganglia pathology [23]

Memory Impairment

• Primarily retrieval deficits (frontal-subcortical pattern) rather than encoding deficits (temporal lobe pattern)
• Working memory particularly affected
• Less severe than in cortical dementias [23]

Processing Speed

• Bradyphrenia (slowed thinking)
• Prolonged reaction times
• Impacts daily functioning [23]

Psychiatric Manifestations (~30-50%)

Psychiatric symptoms often precede neurological signs by months to years, leading to misdiagnosis as primary psychiatric disorders. [23,24]

Mood Disorders

• Depression: Most common (20-40%)
  • May be severe with suicidal ideation
  • Can be reactive or endogenous
  • Often responds to standard antidepressants
• Anxiety: Generalized anxiety, panic attacks, social phobia
• Emotional lability: Inappropriate crying or laughing [23,24]

Behavioral/Personality Changes

• Disinhibition: Impulsivity, inappropriate social behavior
• Apathy: Loss of motivation, social withdrawal
• Irritability and aggression: Personality change noted by family
• Obsessive-compulsive features: Less common [23,24]

Psychotic Disorders

• Psychosis (5-10%): Hallucinations (usually auditory), delusions, thought disorder
• May mimic schizophrenia: Onset in late teens/early twenties
• Key difference: Associated neurological signs, KF rings, abnormal copper studies [23,24]

Cognitive Decline

• "Subcortical dementia" pattern: Slowed cognition, executive dysfunction, personality change
• Rarely progresses to severe dementia: If treated
• Important: Rule out Wilson's in young-onset cognitive impairment [23]

Ocular Manifestations

Kayser-Fleischer Rings

• Appearance: Golden-brown, greenish-gold, or brownish ring at the corneal limbus
• Pathology: Copper deposition in Descemet's membrane (posterior corneal surface)
• Distribution: Typically starts superiorly, then inferiorly, finally 360° ring
• Detection: Slit-lamp examination required for reliable detection; naked eye misses ~50% of cases
• Prevalence:
  • 95-100% of neurological Wilson's disease
  • 50-65% of purely hepatic Wilson's disease
  • Virtually always present if neurological symptoms exist
• Reversibility: May disappear or fade with successful copper chelation therapy (over years)
• Pseudo-KF rings: Can occur in prolonged cholestasis (primary biliary cholangitis), multiple myeloma, hematologic malignancies; but these are distinguishable on slit-lamp examination [3,6,25]

Sunflower Cataracts

• Appearance: Multicolored (red, green, blue) petal-like deposits radiating from central lens
• Location: Anterior and posterior lens capsule
• Frequency: Less common than KF rings (10-20%)
• Significance: Do not impair vision; purely cosmetic
• Reversibility: May regress with treatment [6]

Other Organ System Manifestations

Renal

• Fanconi Syndrome (5-10%): Proximal renal tubular acidosis, aminoaciduria, glucosuria, phosphaturia, uricosuria
• Nephrolithiasis: Calcium and uric acid stones (increased urinary excretion)
• Renal tubular acidosis: Type 2 (proximal) RTA
• Microscopic hematuria and proteinuria: Low-grade
• Rarely: Glomerulonephritis, nephrotic syndrome [20]

Skeletal

• Osteoporosis: Premature bone density loss; present in 50% at diagnosis
• Osteomalacia: Due to renal phosphate wasting and vitamin D deficiency
• Arthropathy:
  • Large joint involvement (knees, wrists, spine)
  • Chondrocalcinosis (calcium pyrophosphate deposition)
  • Osteochondritis dissecans
  • Premature osteoarthritis
• Rickets: In children with untreated disease [2,20]

Cardiac

• Cardiomyopathy (Rare, less than 5%): Dilated or restrictive patterns
• Arrhythmias: Atrial fibrillation, ventricular tachycardia
• Conduction abnormalities: Bundle branch blocks
• Autonomic dysfunction: Orthostatic hypotension, resting tachycardia [20]

Endocrine

• Hypoparathyroidism: Hypocalcemia, hyperphosphatemia; copper deposition in parathyroid glands
• Gynecomastia: In males with cirrhosis (altered sex hormone metabolism)
• Delayed puberty: In children with severe untreated disease
• Amenorrhea and infertility: In females; reversible with treatment
• Subclinical hypothyroidism: Occasionally reported [20]

Hematological

• Coombs-negative hemolytic anemia: Acute copper release (in fulminant hepatic failure or decompensation)
• Anemia of chronic disease: In cirrhosis
• Thrombocytopenia: Hypersplenism in portal hypertension [7,8]

Dermatological

• Hyperpigmentation: Melanin deposition, especially in shins
• Lunulae ceruleae: Blue discoloration of nail lunulae (rare, seen in Asian populations) [2]

---

6. Investigations

Diagnostic Algorithm

A structured approach is essential. The Leipzig scoring system provides a validated diagnostic framework. [3,4]

First-Line Diagnostic Tests

Serum Ceruloplasmin

• Normal range: 0.2-0.6 g/L (20-60 mg/dL)
• In Wilson's disease: less than 0.2 g/L in ~95% of cases
• Interpretation caveats:
  • "Low ceruloplasmin is NOT specific: Also low in:"
    • Hereditary aceruloplasminemia (autosomal recessive CP gene mutation)
    • Severe protein malnutrition
    • Nephrotic syndrome (protein loss)
    • Protein-losing enteropathy
    • Severe hepatic synthetic dysfunction from any cause
    • Menkes disease (X-linked copper deficiency)
  • "Normal or high ceruloplasmin does NOT exclude Wilson's:"
    • 5% of Wilson's patients have low-normal ceruloplasmin
    • Ceruloplasmin is an acute-phase reactant: elevated in inflammation, infection, malignancy, pregnancy, estrogen/oral contraceptive use
    • Heterozygote carriers may have low-normal ceruloplasmin but do NOT develop disease
• Technical: Measured by immunoassay (protein level) or oxidase activity; immunoassay preferred [3,12,26]

24-Hour Urinary Copper

• Normal: less than 40 μg/24 hours (less than 0.6 μmol/24 hours)
• In Wilson's disease (untreated):
  • "> 100 μg/24 hours: Highly suggestive (> 1.6 μmol/24 hours)"
  • "40-100 μg/24 hours: Equivocal; consider repeat testing or penicillamine challenge"
• Interpretation caveats:
  • "False positives: Cholestatic liver disease, autoimmune hepatitis (can have urinary copper 40-100 μg/24h)"
  • "Collection issues: Incomplete 24-hour collection common; verify with creatinine excretion"
  • "In acute liver failure: Urinary copper often massively elevated (> 1000 μg/24h) due to hepatocyte necrosis"
• D-Penicillamine challenge test (if baseline urinary copper equivocal):
  • Administer 500 mg penicillamine orally at 0 and 12 hours
  • Collect urine 0-24 hours
  • "> 1600 μg/24 hours: Highly suggestive of Wilson's disease"
  • Less commonly used with advent of genetic testing [3,4,26]

Slit-Lamp Ophthalmological Examination

• Purpose: Detect Kayser-Fleischer rings and sunflower cataracts
• Technique: Direct visualization with slit-lamp biomicroscopy by experienced ophthalmologist
• KF ring characteristics:
  • Golden-brown, greenish-brown ring at periphery of Descemet's membrane
  • Starts superiorly, then inferiorly, then becomes circumferential
  • Best seen with gonioscopy in subtle cases
• Sensitivity and specificity:
  • Present in 95-100% of neurological Wilson's
  • Present in 50-60% of hepatic-only Wilson's
  • Absence does NOT exclude Wilson's, especially in asymptomatic or purely hepatic cases
• Pseudo-KF rings: Differentiated by distribution and associated conditions (cholestasis, heme malignancies) [3,6,25]

Liver Function Tests

• ALT and AST: Elevated in active hepatic disease (range: mildly elevated to > 1000 IU/L)
• AST:ALT ratio: Often > 2 in cirrhosis and acute liver failure
• Alkaline phosphatase:
  • Normal to mildly elevated in chronic hepatitis
  • "Disproportionately low in acute liver failure: Hallmark feature"
  • "ALP:total bilirubin ratio less than 4 in fulminant Wilson's (bilirubin in mg/dL, ALP in IU/L)"
• Bilirubin: Elevated in acute hepatitis, cirrhosis, acute liver failure
• Albumin: Low in cirrhosis (synthetic dysfunction)
• INR: Elevated in cirrhosis or acute liver failure (coagulopathy) [7,21]

Serum Copper

• Total serum copper: Often LOW in Wilson's disease (paradoxical)
  • "Normal: 70-140 μg/dL (11-22 μmol/L)"
  • Low because 95% of serum copper is bound to ceruloplasmin, which is low
• Non-ceruloplasmin-bound ("free") copper: ELEVATED in Wilson's disease
  • "Calculation: Free copper (μg/dL) = Total copper – (Ceruloplasmin in mg/dL × 3)"
  • "Normal free copper: less than 10-15 μg/dL"
  • "In Wilson's disease: Typically > 25 μg/dL (> 3.9 μmol/L)"
  • Free copper is the toxic fraction
• Exception: In acute liver failure, total serum copper is very HIGH (> 200 μg/dL) due to massive hepatocyte necrosis releasing stored copper [3,26]

Second-Line and Confirmatory Tests

Liver Biopsy with Hepatic Copper Quantification

• Indication: When diagnosis uncertain after first-line tests
• Hepatic copper content:
  • "Normal: less than 50 μg/g dry weight"
  • "Wilson's disease: > 250 μg/g dry weight (often > 500 μg/g)"
  • "Equivocal: 50-250 μg/g (can be seen in chronic cholestasis)"
• Histopathology:
  • Steatosis (macrovesicular and microvesicular)
  • Chronic hepatitis (interface hepatitis, lobular inflammation)
  • Fibrosis (periportal, bridging, cirrhosis)
  • Glycogenated nuclei in hepatocytes (pale, swollen nuclei)
  • "Copper stains (rhodanine, orcein): Insensitive; copper may be diffusely distributed and not visible"
• Caution: Risk of bleeding in coagulopathic patients; contraindicated in severe acute liver failure [3,21,26]

Genetic Testing (ATP7B Gene Sequencing)

• Indication:
  • Confirmatory test when clinical and biochemical tests are suggestive
  • Family screening when proband's mutations are known
  • Diagnosis in patients with equivocal biochemistry
• Yield: Identifies mutations in ~98% of cases if both alleles sequenced (exons + splice sites)
• Interpretation:
  • "Two pathogenic mutations (compound heterozygous or homozygous): Diagnostic"
  • "One mutation identified: May represent heterozygous carrier OR second mutation not detected (deep intronic, regulatory region)"
  • "Variants of uncertain significance (VUS): Common; functional studies or cosegregation analysis needed"
• Limitations:
  • Over 900 known mutations; many private/novel mutations
  • Genotype-phenotype correlation imperfect
  • Does not replace clinical and biochemical diagnosis
• Cost and availability: Increasingly available; turnaround time 4-8 weeks [13,15,16]

Leipzig Scoring System

A validated diagnostic scoring system combining clinical and laboratory features. Score ≥4 indicates high probability of Wilson's disease. [3,4]

Interpretation:

• Total score ≥4: Diagnosis established
• Total score 3: Diagnosis probable; additional tests needed
• Total score 2: Diagnosis possible; additional tests needed
• Total score ≤1: Diagnosis very unlikely

Imaging

MRI Brain

• Indication: All patients with neurological or psychiatric symptoms; consider in asymptomatic for baseline
• Sequences: T1, T2, FLAIR, DWI, SWI (susceptibility-weighted imaging)
• Findings in Wilson's disease:
  • "T2/FLAIR hyperintensity in:"
    • Basal ganglia: Putamen, globus pallidus (most common), caudate, thalamus
    • Midbrain: Tegmentum, red nucleus, substantia nigra
    • Pons, dentate nuclei: In severe cases
  • ""Face of the Giant Panda" sign (midbrain):"
    • Hyperintense tegmentum
    • Hypointense red nuclei and superior colliculi
    • Resembles panda face on axial section
  • ""Eye of the Tiger" sign (rare): Central hypointensity in hyperintense putamen (more common in PKAN, but can occur in Wilson's)"
  • "T1 hyperintensity: In globus pallidus, putamen (copper or manganese deposition, or gliosis)"
  • "SWI hypointensity: Paramagnetic copper accumulation"
  • "Brain atrophy: Cortical, cerebellar, brainstem in chronic untreated disease"
  • "White matter changes: Periventricular, subcortical hyperintensities"
• Correlation with symptoms: Extent of MRI changes correlates poorly with severity of neurological deficit
• Follow-up imaging: May show improvement or stabilization with treatment, but often persistent [18,19,27]

Abdominal Imaging (Ultrasound, CT, MRI)

• Hepatic findings:
  • Increased echogenicity (fatty liver)
  • Hepatomegaly or small shrunken liver (cirrhosis)
  • Nodular liver surface (cirrhosis)
  • Heterogeneous echotexture
• Portal hypertension:
  • Splenomegaly
  • Ascites
  • Portosystemic collaterals, recanalized paraumbilical vein
  • Varices (gastroesophageal)
• FibroScan (transient elastography): Useful for assessing fibrosis stage non-invasively [21]

Hematological Tests (in Acute Presentations)

• Complete blood count:
  • Anemia (hemolytic or chronic disease)
  • Thrombocytopenia (hypersplenism or bone marrow suppression)
  • Leukopenia (hypersplenism)
• Hemolysis workup (if Coombs-negative hemolytic anemia):
  • Elevated unconjugated bilirubin
  • Elevated LDH
  • Low/undetectable haptoglobin
  • Reticulocytosis
  • Spherocytes, schistocytes on blood film
  • "Direct antiglobulin test (DAT/Coombs): NEGATIVE (distinguishes from autoimmune hemolytic anemia) [7,8]"

Renal Function Tests

• Serum creatinine and eGFR: Assess kidney function (may be impaired in hepatorenal syndrome or Fanconi syndrome)
• Urinalysis:
  • Proteinuria (low-grade)
  • Glucosuria (with normal blood glucose in Fanconi syndrome)
  • Microscopic hematuria
• Serum phosphate: Low in renal phosphate wasting (Fanconi syndrome)
• Serum uric acid: Low in uricosuria (Fanconi syndrome)
• Arterial blood gas: Metabolic acidosis (non-anion gap) in proximal RTA [20]

Additional Tests

• Bone densitometry (DEXA scan): Assess for osteoporosis (recommended in all patients at diagnosis)
• Parathyroid hormone and calcium: If clinical suspicion of hypoparathyroidism (hypocalcemia)
• Thyroid function tests: TSH, free T4 (exclude hypothyroidism)
• Echocardiogram: If cardiac symptoms (assess for cardiomyopathy)
• Neuropsychological testing: Formal cognitive assessment in patients with neuropsychiatric symptoms [2,20]

---

7. Management

Wilson's disease is a lifelong disease requiring lifelong treatment. Early diagnosis and treatment are paramount to prevent irreversible organ damage. Untreated Wilson's disease is invariably fatal.

General Principles

1. Start treatment as soon as diagnosis is confirmed (or highly suspected)
2. Treatment is lifelong and must never be discontinued (except temporary cessation for liver transplantation)
3. Choice of initial therapy depends on:
   • Presence/absence of neurological symptoms
   • Severity of hepatic disease
   • Tolerability and side effect profile
4. Presymptomatic patients (detected by family screening) should be treated to prevent symptoms
5. Family screening is mandatory
6. Multidisciplinary care: Hepatologist, neurologist, ophthalmologist, dietitian, psychiatrist (as needed)

Treatment Goals

• Reduce total body copper burden (de-coppering)
• Prevent further copper accumulation
• Prevent or minimize irreversible organ damage
• Improve or stabilize symptoms
• Maintain lifelong remission

Pharmacological Therapy

1. Copper Chelators

Chelators bind copper and promote urinary excretion. Used for initial treatment in symptomatic patients and maintenance therapy.

D-Penicillamine

Mechanism: Binds copper with high affinity, forming soluble complexes excreted in urine

Indications:

• First-line in hepatic Wilson's disease (asymptomatic or symptomatic)
• Second-line in neurological Wilson's disease (due to risk of neurological worsening)

Dosing:

• Initial: 250-500 mg/day in divided doses (before meals, at least 30 minutes before food)
• Maintenance: Gradually increase to 1000-1500 mg/day in 2-4 divided doses
• Pediatric: 20 mg/kg/day divided BID-QID (max 1 g/day initially)

Monitoring:

• Baseline: CBC, urinalysis, LFTs, renal function
• Ongoing (every 2-4 weeks initially, then every 3-6 months):
  • CBC (leukopenia, thrombocytopenia)
  • Urinalysis (proteinuria, hematuria)
  • LFTs
  • 24-hour urinary copper (should increase initially, then normalize)
  • ANA, anti-dsDNA (for drug-induced lupus)

Adverse effects (occur in 20-30%):

• Early hypersensitivity (first 2-3 weeks): Fever, rash, lymphadenopathy, arthralgia
  • "Management: Stop penicillamine 1-2 weeks, restart at lower dose with prednisone cover (20 mg/day tapered over 2 weeks)"
• Hematological:
  • Leukopenia, thrombocytopenia (dose-related; may require dose reduction)
  • Aplastic anemia (rare, less than 1%; requires permanent discontinuation)
• Renal:
  • "Proteinuria (20%): Usually reversible on dose reduction"
  • "Nephrotic syndrome (rare, less than 5%): May require discontinuation"
  • Goodpasture-like syndrome (very rare)
• Dermatological: Elastosis perforans serpiginosa, pemphigus, cutis laxa (long-term)
• Autoimmune: Drug-induced lupus (ANA positive, anti-histone antibodies), myasthenia gravis, polymyositis
• Neurological worsening: 10-50% of patients with neurological Wilson's experience paradoxical worsening in first 2-6 months
  • Thought to be due to mobilization of hepatic copper with redistribution to brain
  • May be irreversible in some cases
  • Consider alternative agents (trientine, zinc) in neurological presentations
• Other: Vitamin B6 deficiency (penicillamine is a B6 antagonist; supplement with pyridoxine 25-50 mg/day), loss of taste, GI upset [1,5,9,28]

Contraindications:

• Pregnancy (relatively contraindicated; see section below)
• Prior severe hypersensitivity or autoimmune reaction
• Severe renal disease

Trientine (Triethylenetetramine Dihydrochloride)

Mechanism: Binds copper and promotes urinary excretion (lower affinity than penicillamine but effective)

Indications:

• First-line in neurological Wilson's disease (lower risk of neurological worsening compared to penicillamine)
• Second-line in hepatic Wilson's disease if penicillamine not tolerated or contraindicated
• Preferred in neurological presentations in many centers

Dosing:

• Adults: 750-1500 mg/day in 2-3 divided doses (on empty stomach, 1 hour before meals)
• Pediatric: 20 mg/kg/day divided BID-TID (max 1.5 g/day)

Monitoring:

• Similar to penicillamine: CBC, urinalysis, LFTs, renal function every 3-6 months
• 24-hour urinary copper

Adverse effects (fewer than penicillamine; occur in less than 10%):

• GI upset: Nausea, dyspepsia (most common)
• Sideroblastic anemia: Rare (trientine chelates iron as well as copper)
• Neurological worsening: Lower incidence than penicillamine (~10-15%)
• Skin reactions: Rare

Advantages over penicillamine:

• Better tolerated
• Lower risk of serious adverse effects
• Lower risk of neurological worsening in neurological presentations

Disadvantages:

• More expensive (historically; now generic available in some countries)
• Chelates iron (avoid iron supplements; monitor ferritin)

CHELATE trial (2022): Randomized controlled trial comparing trientine vs penicillamine for maintenance therapy after initial de-coppering; trientine was non-inferior with better tolerability. [5,9,29]

Tetrathiomolybdate (Investigational/Emerging)

Mechanism:

• Forms tripartite complex with copper and protein, preventing copper uptake
• Binds circulating copper, rendering it non-toxic

Indications:

• Investigational for neurological Wilson's disease
• May have lower risk of neurological worsening

Status:

• Bis-choline tetrathiomolybdate approved in USA (2022) for Wilson's disease
• Not yet widely available globally

Adverse effects: Bone marrow suppression, elevated liver enzymes, anemia [1,5]

2. Zinc Salts

Mechanism:

• Induces metallothionein synthesis in enterocytes and hepatocytes
• Metallothionein binds copper in enterocytes, trapping dietary copper and preventing absorption
• Blocks reabsorption of endogenously secreted copper in GI tract
• Promotes fecal copper excretion (negative copper balance)

Zinc formulations:

• Zinc acetate (preferred; better tolerated)
• Zinc sulfate
• Zinc gluconate

Indications:

• Maintenance therapy after initial de-coppering with chelators
• Monotherapy in presymptomatic/asymptomatic patients (detected by family screening)
• Combination therapy with chelators in severe cases (used sequentially, not simultaneously)
• First-line in pregnancy (safest agent)

Dosing:

• Adults: 150 mg elemental zinc/day in 3 divided doses (50 mg TID)
  • Zinc acetate 50 mg contains ~15 mg elemental zinc (give 170 mg zinc acetate TID = ~50 mg elemental zinc TID)
  • Zinc sulfate 200 mg contains ~50 mg elemental zinc (give 200 mg TDS)
• Pediatric: 75-150 mg elemental zinc/day in 3 divided doses (based on weight)
• Timing: Take on empty stomach (1 hour before or 2-3 hours after meals) to maximize copper-blocking effect

Monitoring:

• 24-hour urinary zinc (should be > 2 mg/day to confirm compliance)
• 24-hour urinary copper (should normalize to less than 75 μg/day)
• Serum copper and ceruloplasmin
• CBC (check for leukopenia, anemia)

Adverse effects:

• GI upset: Nausea, dyspepsia, abdominal pain (10-30%); dose-related
  • Minimize by taking with small protein snack (reduces efficacy slightly but improves compliance)
• Gastritis: Chronic use
• Lipase elevation: Asymptomatic hyperamylasemia/hyperlipasemia
• Sideroblastic anemia: Copper deficiency-induced (rare)

Advantages:

• Excellent long-term safety profile
• No risk of neurological worsening
• Safe in pregnancy
• Inexpensive

Disadvantages:

• Slower onset of action (takes 4-6 months for effective de-coppering)
• Not suitable for initial therapy in symptomatic patients (too slow)
• Requires strict compliance with dosing schedule (TID, empty stomach)
• GI side effects common [1,5,30]

Treatment Strategy by Clinical Presentation

Presymptomatic Patients (Detected by Family Screening)

Rationale: Prevent symptom development and organ damage

First-line: Zinc monotherapy

• Dose: 150 mg elemental zinc/day (50 mg TID, empty stomach)
• Lifelong treatment
• Monitor: Urinary copper and zinc, LFTs, ceruloplasmin every 6-12 months

Alternative: Chelators (if high urinary copper or evidence of subclinical organ involvement)

• Trientine 750-1000 mg/day OR
• Penicillamine 750-1000 mg/day

Outcome: Excellent; most remain asymptomatic indefinitely [10,11,30]

Hepatic Wilson's Disease (Asymptomatic or Symptomatic Chronic Liver Disease)

Initial de-coppering phase (12-24 months):

• First-line: Penicillamine 1000-1500 mg/day OR Trientine 1000-1500 mg/day
• Monitor: 24h urinary copper (expect marked increase initially, then gradual decline), LFTs, CBC

Maintenance phase:

• Option 1: Continue chelator at reduced dose (penicillamine 750-1000 mg/day OR trientine 750-1000 mg/day)
• Option 2: Switch to zinc 150 mg elemental/day (preferred for long-term; better tolerability)

Monitoring:

• LFTs every 3-6 months
• 24h urinary copper every 6-12 months (target less than 125 μg/day on chelators, less than 75 μg/day on zinc)
• Free (non-ceruloplasmin) copper every 6-12 months (target 5-15 μg/dL)
• Slit-lamp examination annually (KF rings should fade/disappear) [1,5,21]

Neurological/Psychiatric Wilson's Disease

Goal: Minimize risk of neurological worsening

Initial de-coppering phase:

• Preferred: Trientine 1000-1500 mg/day (lower risk of neurological worsening)
  • OR Zinc 150 mg elemental/day (slowest but safest; consider in mild/stable cases)
  • OR Tetrathiomolybdate (if available)
• Use with caution: Penicillamine (risk of neurological worsening 10-50%)
  • "If using penicillamine: Start very low dose (250 mg/day), escalate slowly over months, closely monitor neurology"

Maintenance phase:

• Continue trientine at same or reduced dose OR
• Switch to zinc 150 mg elemental/day

Adjunctive neurological therapy:

• Dystonia: Baclofen, trihexyphenidyl, botulinum toxin injections
• Tremor: Propranolol, primidone
• Parkinsonism: Levodopa (often ineffective), dopamine agonists (trial cautiously)
• Psychiatric symptoms: SSRIs for depression/anxiety, atypical antipsychotics for psychosis (avoid typical antipsychotics; worsen dystonia)
• Physical therapy, occupational therapy, speech therapy: Essential

Prognosis:

• Neurological improvement occurs in 40-70% over 2-5 years
• 20-30% stabilize without improvement
• 10-20% continue to worsen despite treatment (especially if treatment started late) [5,9,23]

Fulminant Hepatic Failure (Acute Liver Failure)

Medical therapy (bridge to transplant or in mild cases):

• Chelation (penicillamine, trientine): Generally ineffective in fulminant failure (too slow)
• Plasmapheresis/plasma exchange: Remove free copper; may buy time for transplant
• Continuous renal replacement therapy (CRRT): For hepatorenal syndrome, copper removal
• Supportive care: Intensive care, coagulopathy management, encephalopathy treatment

Definitive therapy: Urgent liver transplantation

• Indications: Most patients with fulminant Wilson's disease require transplant
• Prognostic scores (assess need for transplant):
  • "Revised King's College criteria: Poor predictors in Wilson's"
  • "New Wilson Index: Bilirubin (mg/dL) + INR + AST (IU/L)/100. Score > 11 predicts death without transplant"
  • "Nazer prognostic index: Incorporates bilirubin, INR, AST, WBC, albumin"
• Survival: 80-90% with transplant vs less than 10% without transplant

Post-transplant:

• Liver transplant is curative (provides functional ATP7B)
• Chelation therapy can be discontinued
• Neurological symptoms may improve or stabilize (variable)
• KF rings gradually disappear [7,8,22,31]

Liver Transplantation

Indications:

1. Fulminant hepatic failure (acute liver failure)
2. Decompensated cirrhosis unresponsive to medical therapy
3. (Rarely) Progressive neurological disease refractory to all medical therapy (controversial)

Outcomes:

• 5-year survival: 85-95% (similar to other transplant indications)
• Hepatic recovery: Complete (graft has normal ATP7B function)
• Neurological improvement: Variable; 50% improve, 30% stabilize, 20% no change or worsen
• No need for lifelong chelation: Copper metabolism normalized

Complications:

• Standard transplant complications (rejection, infection, malignancy, immunosuppression side effects) [22,31]

Monitoring on Treatment

Target Parameters on Therapy

Monitoring Schedule

First year of treatment (intensive):

• Months 0-6: Every 4-6 weeks
  • LFTs (ALT, AST, bilirubin, albumin, INR)
  • CBC
  • Urinalysis (if on penicillamine)
  • 24-hour urinary copper
• Months 6-12: Every 2-3 months
  • Same as above

Stable maintenance phase (annual or biannual):

• LFTs every 6-12 months
• 24-hour urinary copper every 6-12 months
• Free copper every 6-12 months
• CBC every 6-12 months
• Slit-lamp examination annually
• Neurological examination annually (if neurological disease)
• Bone density (DEXA) every 2-3 years
• Compliance assessment (critical; non-compliance leads to relapse)

Signs of Treatment Failure or Non-Compliance

• Rising free copper (greater than 25 μg/dL)
• Worsening LFTs after initial improvement
• New or worsening neurological symptoms
• Reappearance or darkening of KF rings
• Rising 24-hour urinary copper on zinc therapy (suggests non-compliance or inadequate dosing)

Note: Non-compliance is the most common cause of treatment failure and disease progression in previously stable patients. Adolescents and young adults are particularly at risk. Regular assessment of medication adherence, using both patient interview and biochemical markers (24-hour urinary zinc for zinc therapy compliance), is essential. [1,5,26,36]

Dietary Modifications

First year of treatment:

• Avoid high-copper foods:
  • Liver, kidney, offal
  • Shellfish (oysters, crab, lobster)
  • Nuts (especially cashews, Brazil nuts)
  • Chocolate and cocoa
  • Mushrooms
  • Whole grains, bran cereals
• Moderate copper foods (limit but not strictly avoid):
  • Legumes (beans, lentils)
  • Dried fruits
  • Avocados

After first year (less restrictive):

• Dietary copper restriction less critical if on effective therapy
• Avoid extremely high-copper foods only

Practical advice:

• Drink water (if copper plumbing, run water 1-2 minutes before drinking)
• Avoid copper-containing multivitamins
• Avoid copper cookware [1,5]

Special Situations

Pregnancy and Wilson's Disease

General principle: Continue treatment throughout pregnancy and lactation. Untreated Wilson's disease poses greater risk to mother and fetus than medications.

Choice of agent:

• Zinc: Safest; first-line in pregnancy
  • "Dose: Same as non-pregnant (150 mg elemental/day)"
• Penicillamine: Can be continued, but reduce dose by 25-50% (to 500-750 mg/day)
  • Risk of teratogenicity (connective tissue defects, cutis laxa) if continued at high dose
• Trientine: Limited data; reduce dose by 25-50%

Management:

• Preconception counseling: Optimize copper control before conception
• Monitor closely: Monthly LFTs, urinary copper, free copper
• Delivery: Vaginal delivery preferred (cesarean if obstetric indication)
• Postpartum: Resume full-dose therapy immediately after delivery

Outcomes:

• Most pregnancies successful if mother compliant with therapy
• Risk of disease worsening if therapy discontinued (do NOT stop) [1,5,32]

Pediatric Wilson's Disease

Presentation: Usually hepatic (less commonly neurological before age 10)

Treatment:

• Same agents as adults, weight-based dosing
• Penicillamine: 20 mg/kg/day (max 1 g/day initially)
• Trientine: 20 mg/kg/day
• Zinc: 75-150 mg elemental/day based on weight

Long-term compliance:

• Challenging in adolescents (lifelong therapy, multiple daily doses)
• Transition to adult care requires careful planning [1,5]

---

8. Complications

Untreated Disease

Treatment-Related Complications

Long-Term Complications (Even with Treatment)

• Residual neurological deficits: Some patients have persistent dystonia, dysarthria, tremor despite treatment
• Cirrhosis complications: Portal hypertension, varices, ascites (if cirrhosis established before treatment)
• Hepatocellular carcinoma (HCC): Rare; risk lower than other causes of cirrhosis, but reported; surveillance recommended if cirrhosis present
• Osteoporosis and fractures: Monitor bone density; vitamin D and calcium supplementation
• Psychiatric morbidity: Depression, anxiety may persist; psychiatric support [1,5,20]

---

9. Prognosis and Outcomes

Overall Prognosis

• With early diagnosis and lifelong treatment: Excellent prognosis; normal or near-normal life expectancy
• Presymptomatic patients (detected by family screening): Remain asymptomatic with zinc or chelator therapy; best outcomes
• Symptomatic patients treated early: Majority achieve clinical stabilization or improvement
• Late-stage disease (advanced cirrhosis, severe neurological disease): Partial improvement or stabilization; some irreversible deficits
• Untreated disease: Invariably fatal within 5-10 years

Prognostic Factors

Favorable:

• Presymptomatic or early symptomatic stage at diagnosis
• Hepatic-only presentation (no neurological involvement)
• Good compliance with lifelong therapy
• Young age at diagnosis

Unfavorable:

• Advanced cirrhosis or fulminant hepatic failure at presentation
• Severe neurological disease at presentation
• Late diagnosis (> 25 years for neurological, > 20 years for hepatic)
• Poor compliance (leading to relapse)

Outcomes by Presentation

Hepatic Wilson's Disease

• Asymptomatic/mild hepatitis: Normalize LFTs in 80-90% within 12 months; excellent long-term outcome
• Cirrhosis (compensated): Stabilization in most; risk of decompensation reduced but not eliminated; HCC surveillance needed
• Cirrhosis (decompensated): Transplant often required; post-transplant survival 85-95% at 5 years
• Fulminant hepatic failure: Transplant required; survival 80-90% with transplant vs less than 10% without

Neurological Wilson's Disease

• Mild neurological symptoms: Improvement in 60-80% over 2-5 years
• Moderate to severe: Improvement in 40-50%, stabilization in 30%, worsening in 20%
• Paradoxical neurological worsening: Occurs in 10-50% initially; may improve over months to years, or be permanent

Psychiatric Wilson's Disease

• Depression, anxiety: Usually improve with copper-lowering therapy; may require antidepressants
• Psychosis: Variable response; some require long-term antipsychotic therapy
• Cognitive impairment: Stabilizes or improves in most; rarely progresses to dementia if treated

Quality of Life

• Patients on stable maintenance therapy: Most report good quality of life comparable to general population
• Impairments: Residual neurological deficits (dysarthria, tremor, dystonia) can impact QOL
• Psychosocial impact: Chronic disease requiring lifelong therapy; genetic implications for family [1,5,23,33]

---

10. Family Screening

Rationale

• Autosomal recessive inheritance: Siblings have 25% risk of being affected, 50% risk of being carriers
• Presymptomatic diagnosis prevents irreversible damage: Early treatment in presymptomatic individuals prevents symptoms and organ damage
• Cost-effective: Screening detects disease before expensive complications develop

Who to Screen

Mandatory:

• All first-degree relatives (siblings, parents, children) of index case

Consider:

• Second-degree relatives if first-degree relatives are carriers
• Offspring of index case (especially if partner is carrier)

Screening Protocol

For siblings and children of index case:

1. If index case's ATP7B mutations are known:

   • Genetic testing first: Test for familial mutations
   • If two mutations (homozygous or compound heterozygous): Affected; proceed to full evaluation
   • If one mutation: Carrier (heterozygote); no disease, no treatment needed
   • If no mutations: Unaffected; no further workup

2. If genetic testing not available or mutations not known:

   • Biochemical screening:
     • Serum ceruloplasmin
     • 24-hour urinary copper
     • Liver function tests (ALT, AST)
     • Slit-lamp examination for KF rings
   • If abnormal: Proceed to full diagnostic workup (liver biopsy, genetic testing)
   • If normal and age less than 5 years: Repeat at age 5-10 years (disease may not be manifest)

For parents:

• Both parents are obligate carriers (each has one ATP7B mutation)
• No treatment needed for carriers
• Genetic counseling for future pregnancies

For extended family:

• Risk depends on relationship and carrier status of intermediate relatives
• Consider genetic counseling [10,11,13]

Management of Presymptomatic Siblings

If diagnosis confirmed:

• Initiate treatment immediately (even if asymptomatic)
• Zinc monotherapy preferred (safe, effective for prevention)
• Monitor as per treatment protocol
• Excellent prognosis; most remain asymptomatic

If carrier (one mutation only):

• No treatment required
• Genetic counseling if planning children (risk to offspring if partner is carrier) [10,30]

---

11. Evidence and Guidelines

Key Guidelines

Landmark Studies and Reviews

1. Członkowska A, et al. Wilson disease. Nat Rev Dis Primers 2018;4:21. PMID: 30190489

   • Comprehensive review of pathophysiology, genetics, clinical features, diagnosis, and treatment
   • Authoritative reference on all aspects of Wilson's disease [1]

2. Bandmann O, et al. Wilson's disease and other neurological copper disorders. Lancet Neurol 2015;14:103-113. PMID: 25496901

   • Detailed review of neurological manifestations and management
   • Emphasis on reducing neurological worsening with initial therapy [5]

3. Schilsky ML, et al. Trientine versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 2022;7:1092-1102. PMID: 36183738

   • CHELATE trial: Trientine non-inferior to penicillamine for maintenance with better tolerability
   • Supports trientine as alternative first-line chelator [29]

4. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008;47:2089-2111. PMID: 18506894

   • AASLD practice guideline; comprehensive diagnostic and treatment algorithms [4]

5. European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 2012;56:671-685. PMID: 22340672

   • EASL guideline; Leipzig scoring system, treatment recommendations [3]

6. García-Villarreal L, et al. Wilson disease: revision of diagnostic criteria in a clinical series with great genetic homogeneity. J Gastroenterol 2021;56:50-58. PMID: 33159804

   • Validation of diagnostic criteria; genotype-phenotype correlations [33]

7. Dev S, et al. Wilson disease: update on pathophysiology and treatment. Front Cell Dev Biol 2022;10:871877. PMID: 35586338

   • Recent comprehensive review of molecular mechanisms and emerging therapies [17]

8. Mulligan C, Bronstein JM. Wilson disease: an overview and approach to management. Neurol Clin 2020;38:417-432. PMID: 32279718

   • Practical approach to neurological Wilson's disease management [2]

9. Nagral A, et al. Wilson's disease: clinical practice guidelines of the Indian National Association for Study of the Liver. J Clin Exp Hepatol 2019;9:74-98. PMID: 30765941

   • Comprehensive guideline from Asian perspective; applicability to resource-limited settings [34]

10. Collins CJ, et al. Direct measurement of ATP7B peptides is highly effective in the diagnosis of Wilson disease. Gastroenterology 2021;160:2367-2382. PMID: 33640437

    • Novel diagnostic approach using ATP7B protein quantification [12]

---

12. Patient and Layperson Explanation

What is Wilson's Disease?

Wilson's disease is a rare inherited condition where the body cannot properly get rid of copper. Copper is a metal that we need in small amounts (it's in many foods like meat, nuts, and chocolate), but too much copper is toxic. In Wilson's disease, copper builds up in the liver and brain, causing damage over time.

How Did I Get It?

Wilson's disease is genetic—you're born with it. You inherited a faulty gene from both your mother and father. Both parents are "carriers" (they have one faulty gene but are healthy). When you get the faulty gene from both parents, you develop Wilson's disease.

It's not contagious—you can't catch it from someone else.

What Are the Symptoms?

Wilson's disease can affect different parts of the body:

Liver problems:

• Tiredness and weakness
• Yellowing of the skin and eyes (jaundice)
• Swelling of the abdomen (fluid buildup)
• In severe cases, liver failure

Brain and nerve problems:

• Shaking (tremor)
• Stiffness and slow movements
• Difficulty speaking clearly
• Difficulty swallowing
• Clumsiness or poor coordination

Mood and thinking problems:

• Depression or anxiety
• Personality changes
• Difficulty concentrating

Eye signs:

• Brown or golden rings around the edge of the colored part of your eye (Kayser-Fleischer rings). These don't affect vision but are an important sign of the disease.

How Is It Diagnosed?

Your doctor will do several tests:

• Blood tests: Check levels of a protein called ceruloplasmin (usually low in Wilson's disease) and copper in your blood
• Urine tests: Measure copper in your urine (usually high)
• Eye exam: Look for Kayser-Fleischer rings using a special microscope (slit lamp)
• Genetic tests: Look for the faulty gene
• Sometimes a liver biopsy (small sample of liver) or brain scan (MRI) if needed

How Is It Treated?

The good news: Wilson's disease is treatable! With treatment, most people live normal lives.

Medications (you'll take these every day for life):

1. Chelators (like penicillamine or trientine): These medicines grab onto copper in your body and help you pee it out.
2. Zinc: This blocks your gut from absorbing copper from food.

Which medicine you take depends on your symptoms and how you tolerate the medicine. Your doctor will monitor you regularly with blood and urine tests.

Diet: In the first year, avoid foods very high in copper (liver, shellfish, nuts, chocolate, mushrooms). After the first year, you can be less strict.

Liver transplant: In rare cases of severe liver failure, you may need a liver transplant. This actually cures the disease (the new liver works normally).

What If I Don't Take My Medication?

This is very important: You must take your medication every day for the rest of your life. If you stop, copper will build up again and the disease will get worse. This can lead to severe liver or brain damage and can be life-threatening.

Can I Live a Normal Life?

Yes! If you take your medication every day:

• Most people with Wilson's disease live a normal lifespan
• You can go to school, work, have relationships, exercise, and do most activities
• Some symptoms (like tremor or stiffness) may improve slowly over months to years, though some people have lasting effects
• You can have children (but you'll need to stay on treatment during pregnancy, usually zinc)

Should My Family Be Tested?

Yes, absolutely. Your brothers and sisters have a 1 in 4 chance (25%) of also having Wilson's disease. It's very important they get tested, because:

• If they have the disease and start treatment before symptoms appear, they can stay completely healthy
• Even if they have no symptoms, they should be tested

Your parents are carriers but don't have the disease and don't need treatment.

Where Can I Get Support?

• Wilson Disease Association (USA): wilsonsdisease.org
• Genetic counseling: Talk to a genetic counselor about family planning
• Support groups: Many hospitals and patient organizations offer support groups
• Talk to your doctor: Ask questions, discuss concerns, and work together on your treatment plan

Key Takeaways

• Wilson's disease is a genetic condition where copper builds up in the liver and brain
• Symptoms can include liver problems, movement problems, and mood changes
• It is diagnosed with blood tests, urine tests, eye exams, and genetic tests
• Treatment is lifelong medication (chelators or zinc) that removes copper
• With treatment, most people live normal, healthy lives
• You must take medication every day—never stop!
• Family members (especially siblings) should be tested

---

13. Examination Focus

High-Yield Exam Topics

For Written Examinations (MCQ/SBA)

Classic presentation scenarios:

1. Young person (less than 40 years) with unexplained liver disease + neurological or psychiatric symptoms
2. Acute liver failure + Coombs-negative haemolytic anaemia + low ALP:bilirubin ratio
3. Movement disorder (dystonia, tremor, parkinsonism) in young adult + liver disease
4. Incidental finding of low ceruloplasmin in asymptomatic young person

Key diagnostic features:

• Low ceruloplasmin (less than 0.2 g/L) + high 24-hour urinary copper (> 100 μg/24h)
• Kayser-Fleischer rings on slit-lamp examination
• Leipzig score ≥4
• ATP7B gene mutations

Pathognomonic findings:

• Kayser-Fleischer rings
• ALP:bilirubin ratio less than 4 in acute liver failure

Treatment principles:

• First-line chelation: Penicillamine or trientine
• Zinc for maintenance or presymptomatic patients
• Liver transplant for fulminant failure
• Lifelong treatment mandatory

For Clinical Examinations (OSCE, Long/Short Cases)

History taking:

• Detailed family history (autosomal recessive, siblings)
• Age of symptom onset
• Progression of liver vs neurological symptoms
• Medication compliance (critical)
• Dietary history

Physical examination signs:

• Neurological: Dystonia (facial, limb), tremor (wing-beating), bradykinesia, dysarthria, ataxia
• Hepatic: Jaundice, hepatomegaly, splenomegaly, ascites, spider nevi, palmar erythema
• Kayser-Fleischer rings: Describe technique for examination (slit-lamp required for definitive diagnosis)

Examination Instructions:

• "Examine this patient with tremor and liver disease"
• "This young man has abnormal movements. Please examine his neurological system."
• "Examine this patient's eyes" (looking for KF rings)

Key examination findings to describe:

• Generalized dystonia with facial involvement (risus sardonicus)
• Wing-beating tremor of upper limbs
• Parkinsonian features (bradykinesia, rigidity, masked facies)
• Slurred, monotonous speech (dysarthria)
• Hepatomegaly with stigmata of chronic liver disease

For Viva Voce (Oral Examinations)

Expected questions and model answers:

Q1: "What is the genetic basis of Wilson's disease?"

• Autosomal recessive disorder caused by mutations in the ATP7B gene on chromosome 13
• ATP7B encodes a copper-transporting ATPase in hepatocytes
• Over 900 mutations identified; H1069Q most common in Europeans
• Results in impaired biliary copper excretion and defective ceruloplasmin synthesis

Q2: "How would you diagnose Wilson's disease?"

• Combination of clinical features, biochemistry, imaging, and genetics
• Biochemistry: Low ceruloplasmin (less than 0.2 g/L), high 24-hour urinary copper (> 100 μg/24h), high free (non-ceruloplasmin) copper
• Slit-lamp examination: Kayser-Fleischer rings
• Liver biopsy: Hepatic copper > 250 μg/g dry weight
• Genetic testing: ATP7B mutations
• Leipzig score: ≥4 confirms diagnosis

Q3: "What is the pathognomonic sign on examination and how is it detected?"

• Kayser-Fleischer rings: Golden-brown copper deposits in Descemet's membrane at corneal limbus
• Detected by slit-lamp examination by ophthalmologist
• Present in 95% of neurological Wilson's, 50% of hepatic Wilson's
• Not visible on naked eye examination in ~50% of cases

Q4: "What are the treatment options for Wilson's disease?"

• Chelators: Penicillamine (first-line), trientine (better tolerated, preferred for neurological)
  • Bind copper, promote urinary excretion
• Zinc salts: Block intestinal copper absorption; used for maintenance or presymptomatic
• Liver transplantation: Curative; indicated for fulminant failure or decompensated cirrhosis
• Lifelong treatment mandatory

Q5: "What is the 'paradox' of penicillamine therapy in neurological Wilson's disease?"

• Up to 50% of patients with neurological symptoms experience worsening during first 2-6 months of penicillamine therapy
• Thought to be due to mobilization of hepatic copper with redistribution to brain
• May be irreversible
• For this reason, trientine or zinc often preferred as initial therapy in neurological presentations

Q6: "What biochemical finding is characteristic of Wilson's disease presenting as acute liver failure?"

• ALP:total bilirubin ratio less than 4 (alkaline phosphatase in IU/L, bilirubin in mg/dL)
• Due to massive hepatocyte necrosis (reduces ALP synthesis) and very high bilirubin
• 94% specific for Wilson's disease in acute liver failure
• Also: AST:ALT ratio > 2.2, Coombs-negative haemolysis, very high serum copper

Q7: "Describe the MRI brain findings in Wilson's disease."

• T2/FLAIR hyperintensity in basal ganglia (putamen, globus pallidus, caudate, thalamus)
• "Face of the Giant Panda" sign: Hyperintense midbrain tegmentum with hypointense red nuclei and superior colliculi (resembles panda face)
• May also see cortical, cerebellar atrophy in advanced disease
• Extent of MRI changes correlates poorly with clinical severity

Q8: "What is the role of family screening in Wilson's disease?"

• Mandatory for all first-degree relatives (siblings, children)
• Siblings have 25% risk of disease
• Presymptomatic diagnosis and treatment prevents irreversible organ damage
• Screening: Ceruloplasmin, urinary copper, LFTs, slit-lamp exam, genetic testing (if proband's mutations known)
• Presymptomatic siblings treated with zinc have excellent outcomes (remain asymptomatic)

Common Exam Pitfalls

Pitfall 1: "Normal ceruloplasmin excludes Wilson's disease"

• Wrong: 5% of Wilson's patients have low-normal ceruloplasmin; ceruloplasmin is an acute-phase reactant (elevated in inflammation)

Pitfall 2: "Kayser-Fleischer rings are always present"

• Wrong: Absent in 50% of purely hepatic Wilson's disease; slit-lamp required (naked eye misses 50%)

Pitfall 3: "Penicillamine is first-line for all Wilson's disease"

• Wrong: Trientine preferred in neurological Wilson's due to lower risk of neurological worsening

Pitfall 4: "Wilson's disease only occurs in children and young adults"

• Wrong: Can present up to 50+ years, though uncommon; median neurological presentation 21 years

Pitfall 5: "Heterozygotes (carriers) need treatment"

• Wrong: Carriers have one mutation, do not develop disease, do not need treatment (only genetic counseling)

Key Clinical Images to Recognize

1. Kayser-Fleischer ring: Golden-brown ring at corneal periphery on slit-lamp
2. MRI brain: T2 hyperintensity in basal ganglia; "Face of the Giant Panda" sign in midbrain
3. Liver histology: Steatosis, chronic hepatitis, cirrhosis; copper stains (rhodanine) may be negative
4. Blood film: Spherocytes, fragmented RBCs (in Coombs-negative haemolytic anaemia)

---

14. Emerging Therapies and Research Directions

Novel Pharmacological Agents

Bis-choline tetrathiomolybdate:

• Approved in USA (2022) for Wilson's disease
• May have lower risk of neurological worsening
• Ongoing studies on long-term efficacy and safety [5]

Gene therapy:

• Preclinical studies using adeno-associated virus (AAV) vectors to deliver functional ATP7B gene to hepatocytes
• Potential curative therapy; still experimental [15]

Small molecule chaperones:

• Aim to stabilize misfolded ATP7B protein (for specific missense mutations)
• Restore protein trafficking and function
• Early-stage research [15]

Biomarkers for Diagnosis and Monitoring

Direct ATP7B protein measurement:

• Quantification of ATP7B peptides in serum using mass spectrometry
• May improve diagnostic accuracy
• Not yet widely available [12]

Exchangeable copper (CuEXC):

• Direct measurement of labile, non-ceruloplasmin-bound copper
• May be more accurate than calculated free copper
• Research tool; limited clinical availability [26]

Neurological Outcome Prediction

• Development of biomarkers to predict which patients will experience neurological worsening with chelation therapy
• Imaging biomarkers (advanced MRI techniques) to predict neurological recovery [19]

---

15. References

Primary Sources

1. Członkowska A, Litwin T, Dusek P, et al. Wilson disease. Nat Rev Dis Primers 2018;4:21. PMID: 30190489. DOI: 10.1038/s41572-018-0018-3.

2. Mulligan C, Bronstein JM. Wilson disease: an overview and approach to management. Neurol Clin 2020;38(2):417-432. PMID: 32279718. DOI: 10.1016/j.ncl.2020.01.005.

3. European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 2012;56(3):671-685. PMID: 22340672. DOI: 10.1016/j.jhep.2011.11.007.

4. Roberts EA, Schilsky ML; American Association for Study of Liver Diseases. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008;47(6):2089-2111. PMID: 18506894. DOI: 10.1002/hep.22261.

5. Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders. Lancet Neurol 2015;14(1):103-113. PMID: 25496901. DOI: 10.1016/S1474-4422(14)70190-5.

6. Singh P, Sharma A, Grewal SPS. Kayser-Fleischer rings: the pathognomonic for Wilson's disease. Clin Case Rep 2024;12(3):e8634. PMID: 38464582. DOI: 10.1002/ccr3.8634.

7. Rajaram S, Vij M, Desai A, et al. Wilson disease in acute liver failure: a helpful flowchart for diagnosis. Semin Respir Crit Care Med 2018;39(5):565-571. PMID: 30485882. DOI: 10.1055/s-0038-1673389.

8. Röhlen DL, Meunier L, Berg T, et al. Acute liver failure due to Wilson's disease: prognostic scores and outcome. Dtsch Med Wochenschr 2025;150(1-02):e1-e10. PMID: 40086863. DOI: 10.1055/a-2462-2582.

9. Litwin T, Gromadzka G, Członkowska A. Neurological deterioration during initial treatment of Wilson's disease. J Neurol Sci 2015;355(1-2):162-166. PMID: 26070661. DOI: 10.1016/j.jns.2015.05.032.

10. Avan A, Hoogenraad TU, Kokot M, et al. Importance of early screening in presymptomatic Wilson's disease. Int J Mol Sci 2022;23(16):9308. PMID: 36012580. DOI: 10.3390/ijms23169308.

11. Huang XY, Lu LL, Li YH, et al. Clinical and genetic characteristics of Chinese Wilson disease patients with early onset. J Clin Lab Anal 2022;36(6):e24420. PMID: 35470480. DOI: 10.1002/jcla.24420.

12. Collins CJ, Yi F, Dayuha R, et al. Direct measurement of ATP7B peptides is highly effective in the diagnosis of Wilson disease. Gastroenterology 2021;160(7):2367-2382.e1. PMID: 33640437. DOI: 10.1053/j.gastro.2021.02.052.

13. Khan S, Cartwright R, Chandak GR, et al. Spectrum of ATP7B mutations in Wilson disease patients from India. Mol Biol Rep 2018;45(6):2445-2456. PMID: 30426382. DOI: 10.1007/s11033-018-4411-4.

14. Huster D. Wilson disease. Best Pract Res Clin Gastroenterol 2010;24(5):531-539. PMID: 20955957. DOI: 10.1016/j.bpg.2010.07.014.

15. Dev S, Kruse R, Hamilton JP, et al. Wilson disease: update on pathophysiology and treatment. Front Cell Dev Biol 2022;10:871877. PMID: 35586338. DOI: 10.3389/fcell.2022.871877.

16. Hsieh YL, Chen HL, Lin YT, et al. Genotype-phenotype correlation in Taiwanese Wilson disease patients. Genet Med 2019;21(11):2430-2437. PMID: 31164752. DOI: 10.1038/s41436-019-0525-4.

17. Dev S, Kruse R, Hamilton JP, et al. Wilson disease: update on pathophysiology and treatment. Front Cell Dev Biol 2022;10:871877. PMID: 35586338. DOI: 10.3389/fcell.2022.871877.

18. Litwin T, Członkowska A. Wilson disease – factors affecting clinical presentation. Parkinsonism Relat Disord 2013;19(11):913-920. PMID: 23890670. DOI: 10.1016/j.parkreldis.2013.06.015.

19. Zimny A, Sławek J, Tarnacka B, et al. Brain MR imaging in neurological Wilson disease. Orphanet J Rare Dis 2023;18(1):160. PMID: 37226184. DOI: 10.1186/s13023-023-02750-1.

20. Wu F, Wang J, Pu C, et al. Wilson's disease: a comprehensive review of the molecular mechanisms. Int J Mol Sci 2015;16(4):6419-6431. PMID: 25809607. DOI: 10.3390/ijms16046419.

21. Saroli Palumbo C, Schilsky ML. Clinical practice update on Wilson disease. Ann Transl Med 2019;7(Suppl 2):S65. PMID: 31179302. DOI: 10.21037/atm.2019.03.54.

22. Weiss KH, Stremmel W. Evolving perspectives in Wilson disease: diagnosis, treatment and monitoring. Curr Gastroenterol Rep 2012;14(1):1-7. PMID: 22109622. DOI: 10.1007/s11894-011-0235-4.

23. Gromadzka G, Bendykowska N, Wierzbicki K, et al. Psychiatric symptoms in Wilson's disease-consequence of ATP7B gene mutations or just coincidence?-possible causal cascades and molecular pathways. Int J Mol Sci 2024;25(22):12393. PMID: 39596417. DOI: 10.3390/ijms252212393.

24. Portala K, Levander S, Westermark K, et al. Pattern of neuropsychological deficits in patients with treated Wilson's disease. Eur Arch Psychiatry Clin Neurosci 2001;251(6):262-268. PMID: 11881841. DOI: 10.1007/s004060170011.

25. Sabhapandit S, Murthy S, Vuppalanchi R, et al. Presence of pseudo-Kayser-Fleischer rings in patients without Wilson disease: a prospective cohort study. Hepatol Commun 2023;7(5):e0108. PMID: 37058122. DOI: 10.1097/HC9.0000000000000108.

26. Ferenci P. Diagnosis of Wilson disease. Handb Clin Neurol 2017;142:171-180. PMID: 28433101. DOI: 10.1016/B978-0-444-63625-6.00014-8.

27. van Wassenaer-van Hall HN, van den Heuvel AG, Algra A, et al. Wilson disease: findings at MR imaging and CT of the brain with clinical correlation. Radiology 1996;198(2):531-536. PMID: 8596863. DOI: 10.1148/radiology.198.2.8596863.

28. Brewer GJ, Askari F, Lorincz MT, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006;63(4):521-527. PMID: 16606763. DOI: 10.1001/archneur.63.4.521.

29. Schilsky ML, Czlonkowska A, Zuin M, et al. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 2022;7(12):1092-1102. PMID: 36183738. DOI: 10.1016/S2468-1253(22)00273-6.

30. Brewer GJ. Zinc acetate for the treatment of Wilson's disease. Expert Opin Pharmacother 2001;2(9):1473-1477. PMID: 11585025. DOI: 10.1517/14656566.2.9.1473.

31. Guillaud O, Dumortier J, Sobesky R, et al. Long term results of liver transplantation for Wilson's disease: experience in France. J Hepatol 2014;60(3):579-589. PMID: 24139676. DOI: 10.1016/j.jhep.2013.10.012.

32. Roberts EA, Sarkar B. Wilson disease in pregnancy. Hepatology 2003;38(6):1602-1603. PMID: 14647074. DOI: 10.1016/j.hep.2003.09.037.

33. García-Villarreal L, Daniels S, Shaw SH, et al. Wilson disease: revision of diagnostic criteria in a clinical series with great genetic homogeneity. J Gastroenterol 2021;56(1):50-58. PMID: 33159804. DOI: 10.1007/s00535-020-01734-0.

34. Nagral A, Sarma MS, Matthai J, et al. Wilson's disease: clinical practice guidelines of the Indian National Association for Study of the Liver, the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition, and the Movement Disorders Society of India. J Clin Exp Hepatol 2019;9(1):74-98. PMID: 30765941. DOI: 10.1016/j.jceh.2018.08.009.

35. Poujois A, Deibener J, Castelnovo G, et al. ATP7B genotype and chronic liver disease treatment outcomes in Wilson disease: worse survival with loss-of-function variants. Hepatol Commun 2022;6(10):2817-2829. PMID: 36096368. DOI: 10.1002/hep4.2062.

36. Shoreibah M, Mahmud N, Bloomer JR. Wilson disease and chronic hepatitis. Liver Int 2019;39(11):2050-2057. PMID: 31250538. DOI: 10.1111/liv.14186.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines. Wilson's disease requires specialist management by experienced hepatologists and neurologists.